GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Apr 9, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Apr 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
Related Tickers: GSK
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on April 9, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not indicate any new material risks.
Key Players & Entities
- GSK plc (company) — The company making the share purchase.
- Citigroup Global Markets Limited (company) — The corporate stockbroker acting on behalf of GSK.
- April 9, 2025 (date) — The date of the announcement and transaction.
FAQ
What was the total number of GSK ordinary shares purchased?
The filing states that GSK purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity in the provided text.
What was the total dollar amount spent on the share repurchase?
The filing does not disclose the total dollar amount of the share repurchase.
Through which entity did GSK conduct these share repurchases?
GSK acted through its corporate stockbroker, Citigroup Global Markets Limited.
What is the par value of GSK's ordinary shares?
The ordinary shares have a par value of 31 1/4 pence each.
Is GSK filing this report as a foreign private issuer?
Yes, the form is a 'REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934'.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 9, 2025 regarding GSK plc (GLAXF).